NO20011933L - Kontrollert frigivende farmasoytiske formuleringer inneholdende en CGMP PDE-5 inhibitor - Google Patents

Kontrollert frigivende farmasoytiske formuleringer inneholdende en CGMP PDE-5 inhibitor

Info

Publication number
NO20011933L
NO20011933L NO20011933A NO20011933A NO20011933L NO 20011933 L NO20011933 L NO 20011933L NO 20011933 A NO20011933 A NO 20011933A NO 20011933 A NO20011933 A NO 20011933A NO 20011933 L NO20011933 L NO 20011933L
Authority
NO
Norway
Prior art keywords
inhibitor
controlled
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
NO20011933A
Other languages
English (en)
Other versions
NO20011933D0 (no
Inventor
Ross James Macrae
Elizabeth King
Original Assignee
Pfizer Res And Dev Co Nv Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011933(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Res And Dev Co Nv Sa filed Critical Pfizer Res And Dev Co Nv Sa
Publication of NO20011933D0 publication Critical patent/NO20011933D0/no
Publication of NO20011933L publication Critical patent/NO20011933L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20011933A 1998-10-23 2001-04-19 Kontrollert frigivende farmasoytiske formuleringer inneholdende en CGMP PDE-5 inhibitor NO20011933L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations
PCT/IB1999/001619 WO2000024383A1 (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Publications (2)

Publication Number Publication Date
NO20011933D0 NO20011933D0 (no) 2001-04-19
NO20011933L true NO20011933L (no) 2001-06-25

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011933A NO20011933L (no) 1998-10-23 2001-04-19 Kontrollert frigivende farmasoytiske formuleringer inneholdende en CGMP PDE-5 inhibitor

Country Status (44)

Country Link
US (1) US6964780B1 (no)
EP (1) EP1123088B1 (no)
JP (1) JP2002528408A (no)
KR (1) KR20010075659A (no)
CN (1) CN1324233A (no)
AP (1) AP2001002125A0 (no)
AT (1) ATE340562T1 (no)
AU (1) AU756509B2 (no)
BG (1) BG65323B1 (no)
BR (1) BR9914718A (no)
CA (1) CA2348086C (no)
CO (1) CO5160262A1 (no)
CR (1) CR6326A (no)
CY (1) CY1106239T1 (no)
CZ (1) CZ20011427A3 (no)
DE (1) DE69933383T2 (no)
DK (1) DK1123088T3 (no)
DZ (1) DZ2923A1 (no)
EA (1) EA004068B1 (no)
EE (1) EE200100235A (no)
ES (1) ES2272082T3 (no)
GT (1) GT199900184A (no)
HK (1) HK1041818A1 (no)
HR (1) HRP20010285A2 (no)
HU (1) HUP0104318A3 (no)
ID (1) ID28232A (no)
IL (1) IL141764A (no)
IS (1) IS5865A (no)
MA (1) MA26700A1 (no)
MX (1) MXPA01004011A (no)
MY (1) MY130727A (no)
NO (1) NO20011933L (no)
NZ (1) NZ510275A (no)
OA (1) OA11664A (no)
PA (1) PA8484301A1 (no)
PE (1) PE20001286A1 (no)
PL (1) PL195789B1 (no)
PT (1) PT1123088E (no)
SK (1) SK286473B6 (no)
TR (1) TR200101103T2 (no)
TW (1) TW577756B (no)
UA (1) UA67802C2 (no)
UY (1) UY25765A1 (no)
WO (1) WO2000024383A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
SK287674B6 (sk) 1998-11-02 2011-05-06 Elan Pharma International Limited Mnohočasticový prostriedok s modifikovaným uvoľňovaním obsahujúci metylfenidát, pevná orálne dávková forma s jeho obsahom a jeho použitie
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1264574C (zh) 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
MX347237B (es) 2004-05-11 2017-04-20 Eb Ip Lybrido B V Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
US20110244050A1 (en) 2008-12-12 2011-10-06 Siegfried Rhein S.A. De C.V. Pulsed-release sildenafil composition and method for preparing said composition
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
JP6121990B2 (ja) 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
DK0941075T3 (da) * 1997-01-06 2003-07-14 Pfizer Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DK1109814T3 (da) * 1998-09-04 2004-08-02 Ortho Mcneil Pharm Inc 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion

Also Published As

Publication number Publication date
MY130727A (en) 2007-07-31
KR20010075659A (ko) 2001-08-09
CZ20011427A3 (cs) 2001-10-17
EE200100235A (et) 2002-08-15
HRP20010285A2 (en) 2002-06-30
UA67802C2 (uk) 2004-07-15
TR200101103T2 (tr) 2001-09-21
IL141764A (en) 2008-06-05
HK1041818A1 (zh) 2002-07-26
PL347476A1 (en) 2002-04-08
UY25765A1 (es) 2001-08-27
DK1123088T3 (da) 2007-01-02
ID28232A (id) 2001-05-10
EA200100298A1 (ru) 2001-08-27
TW577756B (en) 2004-03-01
GT199900184A (es) 2001-04-14
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
DZ2923A1 (fr) 2004-03-01
EP1123088A1 (en) 2001-08-16
PA8484301A1 (es) 2000-09-29
NZ510275A (en) 2003-07-25
MXPA01004011A (es) 2003-03-10
AU5878799A (en) 2000-05-15
MA26700A1 (fr) 2004-12-20
SK286473B6 (sk) 2008-11-06
CY1106239T1 (el) 2011-06-08
HUP0104318A3 (en) 2003-12-29
ES2272082T3 (es) 2007-04-16
CA2348086C (en) 2007-01-23
CO5160262A1 (es) 2002-05-30
PE20001286A1 (es) 2000-11-22
JP2002528408A (ja) 2002-09-03
CN1324233A (zh) 2001-11-28
US6964780B1 (en) 2005-11-15
WO2000024383A1 (en) 2000-05-04
DE69933383D1 (de) 2006-11-09
IL141764A0 (en) 2002-03-10
CA2348086A1 (en) 2000-05-04
SK5192001A3 (en) 2002-09-10
BR9914718A (pt) 2001-07-10
HUP0104318A2 (hu) 2002-03-28
IS5865A (is) 2001-02-27
BG65323B1 (bg) 2008-02-29
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
EP1123088B1 (en) 2006-09-27
NO20011933D0 (no) 2001-04-19
DE69933383T2 (de) 2007-02-01
PT1123088E (pt) 2007-01-31
PL195789B1 (pl) 2007-10-31
AU756509B2 (en) 2003-01-16
ATE340562T1 (de) 2006-10-15
OA11664A (en) 2005-01-07

Similar Documents

Publication Publication Date Title
NO20011933D0 (no) Kontrollert frigivende farmasöytiske formuleringer inneholdende en CGMP PDE-5 inhibitor
IT1313549B1 (it) Formulazioni farmaceutiche a base di epotilone 3
IS5524A (is) Forðatöflur til inntöku
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IS5541A (is) Áfangatöflur til inntöku
ID22939A (id) Formulasi-formulasi farmasi yang mengandung vorikonozal
DE69824231D1 (de) Bioadhäsive Tabletten
ID23299A (id) Formulasi-formulasi farmasi
EE200000693A (et) Uudsed makroosakeste formulatsioonid
DK0966287T3 (da) Oxacarbazepinfilmovertrukne tabletter
DE69807420T2 (de) Pharmazeutische aerosolzusammensetzung
MA24473A1 (fr) Formulations
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
EE9900545A (et) Farmatseutiline kompositsioon
DE69830154D1 (de) Pharmazeutische zusammensetzungen
ATE243999T1 (de) Pharmazeutische zusammensetzungen enthaltend zafirlukast
DE69706833D1 (de) Pharmazeutische zusammensetzungen enthaltend famciclovir monohydrat
NO983259D0 (no) Famciclovir tabletter
DE69814616D1 (de) Schnellfreisetzende komprimierte flurbiprofen enthaltende tablette
DE29813269U1 (de) Tablette
ID19162A (id) Komposisi farmasi yang mengandung trehalosa
ID21180A (id) Senyawa-senyawa farmasi

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application